Multiple sclerosis

• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Recruitment ended
  2022-502611-10-00 5 2020-11-24 "Primary Progressive Multiple Sclerosis (PPMS)"
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc … Recruitment ended
  2023-506515-18-00 5 2020-10-23 "Primary Progressive Multiple Sclerosis (PPMS)"
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Recruitment ended
  2023-506467-34-00 5 2020-10-20 "Relapsing Multiple Sclerosis (MS)"
• Effect of cladribine treatment on microglial activation in the CNS Recruitment ended
  2024-519921-39-00 6 2019-08-16 "Multiple Sclerosis"
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Recruitment ended
  2023-506429-13-00 5 2018-05-02 "Progressive multiple sclerosis (PMS)"
• A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS Halted
  2023-507874-42-00 9 2024-08-27
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) Halted
  2023-507820-22-00 3 2024-05-22 "Progressive Multiple Sclerosis (PMS)"
• A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in th … Ended
  2025-523791-24-00 3 2026-01-08
• A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combi … Ended
  2025-521754-41-00 3 2025-08-15
• Dendritic cell therapy combined treatment in multiple sclerosis Ended
  2024-519975-24-00 4 2025-01-13
• A study to investigate the pharmacokinetics of remibrutinib in CSF in healthy participants. Ended
  2023-506760-13-00 3 2023-12-11 "Healthy"
• A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Gl … Ended
  2023-506863-32-00 3 2023-07-25 "Multiple Sclerosis (MS)"
• A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant … Ended
  2023-509078-45-00 4 2022-12-19
• A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous (SC) Ocrelizumab … Ended
  2023-505975-54-00 5 2022-03-28 "Multiple Sclerosis (MS)"
• A Study to Evaluate B Cell Levels in Infants Potentially Exposed to Ocrelizumab During Pregnancy - The MINORE Study Ended
  2024-510974-25-00 6 2021-11-10 "Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS"
• A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended
  2023-506543-41-00 5 2018-07-25 "Multiple sclerosis (MS)"
• A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How … Ended
  2024-513639-26-00 3 "Multiple Sclerosis (MS)"
• A phase IV, unicentric, open label clinical trial to evaluate the default mode network in multiple sclerosis patients on Cladribine treatmen … Expired
  2023-504577-21-00 6 "Multiple Sclerosis"

Showing 25–42 of 42 trials